Haemonetics is expected to report Q2 2026 revenue of $327.9 million and earnings per share of $1.07, with the current stock price of $85.54 trading close to the average analyst target of $87.90.
Investors are primarily focused on the organic growth of the Plasma segment, which remains the company’s most significant growth driver.
Following the strategic divestiture of its whole blood business, the market is looking for evidence that double-digit plasma volume growth and the expansion of the VASCADE vascular closure portfolio can sustain long-term profitability. Management’s ability to rebound in the Interventional Technologies segment while maintaining adjusted operating margins of 26-27% will be critical for achieving recently issued fiscal 2027 guidance.